Übersetzung für "Arteriellen verschlusskrankheit" in Englisch

There are various causes of peripheral arterial disease.

These are aimed towards the treatment of arterial occlusive disease.

What to do about Peripheral Arterial Disease?

Outside the coronary arteries, percutaneous transluminal angioplasty is used primarily in the case of peripheral artery occlusion disease.

If peripheral arterial occlusive disease occurs, the blood flow in the legs is disrupted.

This is a very realistic demonstration and simulation of the treatment for peripheral arterial disease (PAD).

The progression of the pain can be broken down into four stages of peripheral arterial disease.

Peripheral vascular disease restricts or stops blood flow to the legs.

Peripheral Arterial Disease affects over 800,000 Canadians and over 8 Million Americans.

There are limited clinical trial data in patients with ischaemic heart disease and/ or peripheral arterial disease.

The body needs the pressure gradient between arteries and veins in order for the heart to pump blood forward through arteries and into veins.

There are limited clinical trial data in patients with ischaemic heart disease and/or peripheral arterial disease.

The experts were first asked to discuss the current standard approach to the clinical management of peripheral arterial occlusive disease (PAOD), the characteristics of the patients treated with cilostazol and the clinical relevance of the benefits of cilostazol.

Cilostazol is a medicine that is used to improve walking distance in patients who have intermittent claudication due to peripheral arterial obstructive disease (obstruction and narrowing of the arteries of the limbs, leading to reduced blood flow).

Warnings and Precautions Talk to your doctor before using Revatio if you: - have a disease due to a blocked or narrow vein in the lungs rather than a blocked or narrow artery.

Aim of the study was to examine whether patients with an occlusive arterial disease (OAD) have acquired colour vision disturbances and whether a coronary heart disease (CHD) has an influence to the results.

This pain only recedes while resting, and as a result, sufferers of peripheral arterial disease often have to stop every few yards.

For example, the clinical effectiveness of BEMER Physical Vascular Therapy as an effective complementary therapy option in peripheral arterial disease has been proven by way of a controlled study.

We would like to introduce our ABPI MD in every clinic to help physicians discover peripheral arterial disease.

In a case of occlusive peripheral and coronary artery disease, the remedy Bismuth subsalicylicum combines the destructive stage 15 of the Gold series, related to the heart and circulation, with the blood-thinning quality of salicylic acid.

Treatment of peripheral vascular disease involves lifestyle changes, treating any other medical conditions and, sometimes, surgery.

If a sufferer believes that they are experiencing the first signs of peripheral arterial disease, they should definitely seek medical advice so that their doctor can initiate any necessary treatment.

For example, just over a month ago we received marketing authorization for Xarelto in the United States in another indication: treatment of coronary artery disease and peripheral artery disease, a condition where the blood flow to the legs is reduced.

For example, this year we might receive marketing authorization in Europe and the United States for the use of XareltoTM in a further indication: the treatment of coronary heart disease and peripheral artery disease, also known as intermittent claudication.

About CLI In the US alone, it is estimated that 8-12 million people suffer from Critical Limb Ischemia (CLI) associated with Peripheral Artery Disease (PAD).

Critical Limb Ischemia (CLI) is a progressive form of peripheral arterial disease, which blocks the arteries in the lower extremities, resulting into reduction of the blood flow. It is a debilitating disease which affects patients with severe pain in the feet or toes.

This impedes blood flow, although in the early stages of peripheral arterial disease, this often does not cause any symptoms while resting.

Leverkusen, Germany / San Carlos, Calif., U.S. - Bayer HealthCare (BHC) and Nuvelo Inc. (Nasdaq: NUVO) today announced that they had begun patient enrollment in a second pivotal phase III clinical trial of alfimeprase for the treatment of acute peripheral arterial occlusion (PAO).